Seeking Alpha

Seeking Alpha Portfolio App for iPad

8,270 people get TEVA articles and Market Currents by email alert.

Get email alerts on TEVA »

TEVA

Teva Pharmaceutical Industries Limited

5/21/2013, 2:56 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 9:11 AM Alexza Pharmaceuticals (ALXA) comes off trading halt, now up 52% premarket following the license deal with Teva (TEVA +0.3% premarket). The conference call discussing the matter is underway. 3 Comments [Breaking News, Healthcare, On the Move]
Wednesday, May 8, 9:00 AM Alexza Pharmaceuticals (ALXA) announces an exclusive U.S. license deal for Adasuve with Teva Pharmaceutical (TEVA). Nice deal for Alexza - it will receive an upfront payment of $40M with eligibility for another $195M based on milestones. Conference call to discuss is about to begin. Shares remains halted. (PR) Comment! [Healthcare, Breaking News]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Friday, May 3, 5:43 PM An FDA panel has voted 17-1 that Amgen's (AMGN) blood-boosting drugs would benefit radiation survivors in the event of a nuclear attack. The drugs, known as Leukocyte growth factor drugs, are normally given to cancer patients to combat the effects of chemotherapy. The panel observed monkeys exposed to radiation, and those given AMGN's Neupogen showed a greater likelihood of survival, and the FDA says it's likely to provide the same benefit to people as well. Comment! [Healthcare]
Thursday, May 2, 7:03 AM Teva Pharma (TEVA): Q1 EPS of $1.12 beats by $0.01. Revenue of $4.9B beats by $0.05B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 29, 10:28 AM Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription performance. According to data, the drug has already garnered nearly 8% of the multiple sclerosis market through the week ended April 19, with prescriptions up 120% over the prior week. By comparison, Novartis' (NVS) Gilenya saw a market share drop to 6%. RBC sees performance on track to meet quarterly sales expectations. Comment! [Healthcare, On the Move]
Wednesday, April 17, 9:11 AM Teva (TEVA) provides an update on a Phase III trial for Milprosa: 1) further evidence that the ring "is comparable to progesterone gel in efficacy"; 2) at eight weeks, multiple pregnancy rates were higher for those treated with Milprosa compared to gel; 3) multiple live birth rates were higher with Milprosa. (Previously: progesterone hormone supplement effective for women undergoing IVF treatment) 5 Comments [Healthcare]
Friday, April 12, 12:22 PM Generic giant Teva Pharmaceuticals (TEVA -2%) slides today after CNBC's Jim Cramer recommended selling the stock earlier, as the company appears to be underperforming its peers. Cramer also warned that the looming patent expiry for its MS treatment Copaxone, which accounts for 20% of TEVA's sales and is set to expire in 2015, makes a ripe target for other generic manufacturers. 5 Comments [Healthcare, On the Move]
Monday, April 8, 2:42 PM Teva (TEVA -0.8%) makes a couple of top level announcements in Japan/Asia today, appointing Ichiro Kikushige as CEO of Teva Seiyaku, Japan, and Yoo Suk Hong as the first Chief Executive Officer of the business venture established between TEVA and South Korea's Handok Pharmaceuticals. Mr. Kikushige most recently was Senior Director of Sales for Eli Lilly Japan, and will replace Makoto Shimada, current President and CEO, who is retiring after a 40 year career in the industry. Comment! [Healthcare, Global & FX]
Friday, April 5, 8:01 AM Antares Pharma (ATRS) gets a Notice of Allowance from the U.S. Patent Trade Office regarding the company's patent application for the VIBEX QuickShot. ATRS said Thursday that the first shipment of the auto-injector devices will be on their way to Teva (TEVA) by the end of Q1. Shares +2% premarket. 1 Comment [Healthcare, On the Move]
Thursday, April 4, 4:00 PM Synthetic Biologics (SYN +4.3%), which was trading lower on the session, jumps after saying a patent issued to the University of California "includes claims to the use of [the company's] drug candidate Trimesta in combination" with Copaxone, Teva's (TEVA -0.8%) annual $14B selling multiple sclerosis drug. 1 Comment [Healthcare, On the Move]
Wednesday, April 3, 12:37 PM Antares Pharma (ATRS +0.3%) says the first shipment of commercial-ready VIBEX auto-injector devices will be shipped to TEVA at the end of Q1. Anatares will receive a negotiated purchase price for each device sold, as well as a royalty on sales. 1 Comment [Healthcare, Global & FX]
Tuesday, April 2, 3:22 AM A district court has ruled that a patent protecting AstraZeneca's (AZN) billion-dollar Pulmicort Repsules asthma treatment is invalid, opening the way for Actavis (ACT) to launch a generic version. The ruling won't affect AstraZeneca's 2013 revenue guidance, but it will hurt royalties that the company receives from Teva's (TEVA) version of Pulmicort. It's a further blow for AstraZeneca as it restructures amidst a patent cliff. (PR) Comment! [Healthcare, Top Stories]
Wednesday, March 27, 4:12 PM Shares of Teva (TEVA -1.2%) close lower today on the back of Biogen's (BIIB +3%) earlier announcement of FDA approval for its MS capsule Tecfidera. Earlier in the week, TEVA had announced its own successful results from Phase III testing for its Multiple Sclerosis drug Laquinimod. Comment! [Healthcare, Global & FX, On the Move]
Monday, March 25, 5:29 AM The Supreme Court is due to hear a "pay for delay" a case today over whether it's legal for drug companies to pay generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The case is the FTC vs Actavis (ACT) and involves Abbott Labs' (ABT) AndroGel testosterone treatment. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation.
7 Comments [Healthcare, Top Stories]
Thursday, March 21, 8:21 AM Teva (TEVA +0.25%) and Active Biotech (ATVBF.PK) say that early treatment of Multiple Sclerosis with their Laquinimod drug significantly cuts the risk of disability progression in patients, a Phase III trial shows. Additional data from an animal preclinical study demonstrates that laquinimod can restore myelination in the brain and spinal cord. (PR) 3 Comments [Healthcare]

1
2
3
4
5
6
...
15
Next Page